Lexicon Pharma Stock: Significant Upside Tied To Successful Inpefa Commercialization


Heart attack and heart disease. 3d illustration

Mohammed Haneefa Nizamudeen

It’s been an interesting few months for Lexicon Pharmaceuticals (NASDAQ:LXRX) since I last wrote about this small, commercialization-stage biotech. While the share price fell below $1 on a few occasions, increased optimism around the company’s efforts to get


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *